<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="52892">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02417610</url>
  </required_header>
  <id_info>
    <org_study_id>22/14</org_study_id>
    <nct_id>NCT02417610</nct_id>
  </id_info>
  <brief_title>Comparative Assessment of Viscosupplementation With Polynucleotides and Hyaluronic Acid</brief_title>
  <acronym>PNHA1401</acronym>
  <official_title>Comparative Assessment of Viscosupplementation With Polynucleotides and Hyaluronic Acid to Viscosupplementation With Hyaluronic Acid in the Treatment of Osteoarthritis of the Knee. Randomized, Double-blind, Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Ortopedico Rizzoli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Ortopedico Rizzoli</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the validity of the polynucleotide within the intra
      articular treatment of osteoarthritis of the knee, comparing it with that of hyaluronic
      acid, the most commonly used.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>KSS (Knee society score)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Synovial fluid analysis</measure>
    <time_frame>3 weeks</time_frame>
    <description>Morphological analysis and blood white cell count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth factor contained in synovial fluid determinations</measure>
    <time_frame>3 weeks</time_frame>
    <description>Total protein content, IL1beta, IL6, IL8, TNFalpha, MMP1</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Polynucleotide - PNHA - Newart</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 patients will be enrolled and treated with three weekly injections of polynucleotide plus hyaluronic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyaluronic acid - HA - Ialart</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 patients will be enrolled and treated with three weekly injections of hyaluronic acid</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Polynucleotide - PNHA - Newart</intervention_name>
    <description>gel polynucleotides and hyaluronic acid</description>
    <arm_group_label>Polynucleotide - PNHA - Newart</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hyaluronic acid - HA - Ialart</intervention_name>
    <description>Hyaluronic acid</description>
    <arm_group_label>Hyaluronic acid - HA - Ialart</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 50 and 75 years

          -  Patients informed consent

          -  Knee OA (Osteoarthritis) (ACR classification) with a Kellgren Laurence from 1 to 4

          -  Knee pain from arisen at least 2 months

          -  BMI lower than 40

        Exclusion Criteria:

          -  Pregnancy or lactation

          -  Severe systemic disorders

          -  History of drug abuse or alcoholism

          -  Hypersensibility to Hyaluronic acid or Polynucleotide

          -  No previous intra articular infiltration (from 3 months)

          -  No steroidal or anticoagulant systemic therapy from one month

          -  Knee articular deformity

          -  Patients affected by rheumatoid arthritis or other inflammatory articular pathologies
             and hematological disorders

          -  Focal skin lesion in the anatomical site of injections
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dante Dallari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Ortopedico Rizzoli</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dante Dallari, MD</last_name>
    <phone>0516366138</phone>
    <phone_ext>0039</phone_ext>
    <email>dante.dallari@ior.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Istituto Ortopedico Rizzoli</name>
      <address>
        <city>Bologna</city>
        <zip>40136</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dante Dallari, MD</last_name>
      <phone>0516366138</phone>
      <phone_ext>0039</phone_ext>
      <email>dante.dallari@ior.it</email>
    </contact>
    <contact_backup>
      <last_name>Giacomo Sabbioni, MD</last_name>
      <phone>0516366699</phone>
      <phone_ext>0039</phone_ext>
      <email>giacomo.sabbioni@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <lastchanged_date>April 14, 2015</lastchanged_date>
  <firstreceived_date>February 17, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Ortopedico Rizzoli</investigator_affiliation>
    <investigator_full_name>Giacomo Sabbioni</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Polynucleotide</keyword>
  <keyword>Hyaluronic acid</keyword>
  <keyword>Intra articular injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
